Invezz
23 Oct 2026, 17:50 UTC · 1h ago
Moderna leaked data was positive, what's hurting MRNA stock then?
Impact · against what's priced in
The leaked Phase 3 data for the cancer vaccine is a non-event for both stocks as the market had already priced in the trial's success. For Moderna, the news highlights a gap between clinical validation and commercial scalability, reinforcing the current valuation pressure.
- MRNA−0.10
Already priced in
- The price assumes
The successful Phase 3 INTerpath-001 melanoma trial results and the validation of the mRNA oncology platform
The price already paid for the successful melanoma trial results following the August announcement; the lack of overall survival data prevents the stock from moving toward the high-end bull case targets.
What MRNA's price assumes · Sep 11
